These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. Cohen JA; Chun J Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239 [TBL] [Abstract][Full Text] [Related]
3. Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. Groves A; Kihara Y; Chun J J Neurol Sci; 2013 May; 328(1-2):9-18. PubMed ID: 23518370 [TBL] [Abstract][Full Text] [Related]
4. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T; Horakova D; Spelman T; Jokubaitis V; Trojano M; Lugaresi A; Izquierdo G; Rozsa C; Grammond P; Alroughani R; Duquette P; Girard M; Pucci E; Lechner-Scott J; Slee M; Fernandez-Bolanos R; Grand'Maison F; Hupperts R; Verheul F; Hodgkinson S; Oreja-Guevara C; Spitaleri D; Barnett M; Terzi M; Bergamaschi R; McCombe P; Sanchez-Menoyo J; Simo M; Csepany T; Rum G; Boz C; Havrdova E; Butzkueven H; Ann Neurol; 2015 Mar; 77(3):425-35. PubMed ID: 25546031 [TBL] [Abstract][Full Text] [Related]
5. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Bergvall N; Lahoz R; Reynolds T; Korn JR Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Chun J; Hartung HP Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis. O'Day K; Meyer K; Miller RM; Agarwal S; Franklin M J Med Econ; 2011; 14(5):617-27. PubMed ID: 21777161 [TBL] [Abstract][Full Text] [Related]
8. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186 [TBL] [Abstract][Full Text] [Related]
10. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C; JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807 [TBL] [Abstract][Full Text] [Related]
11. [Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature]. Shmyrev VI; Kryzhanovskiĭ SM; Danilycheva IV Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(2 Pt 2):93-7. PubMed ID: 22677684 [TBL] [Abstract][Full Text] [Related]
12. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487 [TBL] [Abstract][Full Text] [Related]
13. Azathioprine in multiple sclerosis. Invernizzi P; Benedetti MD; Poli S; Monaco S Mini Rev Med Chem; 2008 Aug; 8(9):919-26. PubMed ID: 18691149 [TBL] [Abstract][Full Text] [Related]
14. New disease-modifying therapies and new challenges for MS. Yadav V; Bourdette D Curr Neurol Neurosci Rep; 2012 Oct; 12(5):489-91. PubMed ID: 22760478 [TBL] [Abstract][Full Text] [Related]
15. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894 [TBL] [Abstract][Full Text] [Related]
16. Switching from natalizumab to fingolimod: an observational study. Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398 [TBL] [Abstract][Full Text] [Related]